Megan McCloskey Dow
Recent Quotes
"We reiterate our Buy recommendation for GALE."
—
Megan McCloskey Dow, MLV & Co
(11/13/12)
more >
"New data lends more support to the clinical potential of GALE's NeuVax."
—
Megan McCloskey Dow, MLV & Co
(10/26/12)
more >
"We are initiating coverage of GALE with a Buy rating."
—
Megan McCloskey Dow, MLV & Co
(10/24/12)
more >
"IMUC's ICT-107 data show immune response to broader glioma antigens."
—
Megan McCloskey Dow, MLV & Co
(6/4/12)
more >
"IMUC is committed to growing its pipeline."
—
Megan McCloskey Dow, MLV & Co
(5/25/12)
more >
"We are initiating coverage on IMUC, which has promising results from a phase 1 trial of ICT-107."
—
Megan McCloskey Dow, MLV & Co
(5/15/12)
more >
